Connect with us

health

NAFDAC urged to probe KissKids diaper claims

Published

on

NAFDAC

Consumer advocates call for an independent quality assessment after a viral TikTok video alleged foreign material was found inside a baby diaper

adron lemon friday

Nigerian health and consumer protection regulators, including the National Agency for Food and Drug Administration and Control, NAFDAC, have been urged to independently investigate KissKids diaper claims after a viral TikTok video raised questions about the quality and safety of a baby diaper product.

Also read: NAFDAC Warns of Fake Herceptin 600mg in Nigeria

The call followed a video posted by a Nigerian mother who alleged that she discovered a black foreign material inside a KissKids baby diaper after using 36 of the 40 diapers in a pack.

In the video, the woman expressed concern that the unidentified object could potentially have posed a health risk to an infant had it gone unnoticed.

The post quickly attracted attention on social media, prompting conversations among parents and consumers about product safety, manufacturing standards and quality control in the infant care industry.

The woman later deleted the original video and posted another recording in which she said representatives of the company had contacted her, addressed her complaint and provided replacement products.

She also commended the company’s customer service and responsiveness.

There is, however, no publicly available evidence explaining why the original video was removed beyond the account provided by the woman herself. Similarly, claims circulating online that she was persuaded or compensated to delete the post remain unsubstantiated.

Despite the apparent resolution of the individual consumer complaint, public affairs commentator Femi Omidiji said the underlying safety concern deserved independent regulatory attention.

“The safety of infants should never be left to speculation,” Omidiji said.

“Whenever questions arise about products that come into direct contact with babies’ skin, regulators have a duty to establish the facts through a prompt, transparent and independent investigation. Public confidence is best protected when concerns are addressed with evidence rather than assumptions.”

An email sent to KissKids seeking the company’s official response to the allegation had not received a response as of the time of filing this report.

Omidiji said regulators should determine whether the reported incident was an isolated manufacturing defect, contamination during production or packaging, or whether the affected product met all applicable safety and quality standards.

He stressed that an independent investigation should not automatically be interpreted as an accusation against the manufacturer.

“An independent investigation should not be interpreted as a declaration of guilt against the manufacturer,” he said. “Rather, it is a standard consumer protection measure designed to reassure the public that products intended for babies continue to meet the highest safety and quality standards.”

Baby diapers are designed for prolonged contact with an infant’s sensitive skin, making strict quality control and product safety particularly important.

Omidiji said the incident highlighted the need for manufacturers to maintain rigorous production standards, comprehensive batch testing, product traceability and continuous quality assurance.

“Quality control systems exist to prevent defective products from reaching consumers. Whenever questions arise about those systems, transparency becomes just as important as the investigation itself,” he added.

While acknowledging the company’s reported decision to engage with the consumer and replace the affected products, Omidiji said customer service should complement rather than substitute formal product safety checks.

“Responding swiftly to consumer complaints reflects responsible corporate conduct. However, where allegations involve potential product defects, an independent quality assurance assessment remains essential to protect consumers and strengthen public confidence,” he said.

He suggested that regulators could examine the affected product batch, review relevant production records and, where necessary, conduct laboratory analysis and factory inspections to establish the facts.

Such an approach, he argued, would protect consumers while also giving manufacturers an opportunity to address potentially unfounded allegations with credible evidence.

If an investigation confirms that the product meets the required safety standards, Omidiji said the findings could help restore consumer confidence. If deficiencies are identified, timely corrective action could reduce the risk of similar incidents occurring in the future.

At the time of filing this report, no Nigerian regulatory agency had publicly announced the outcome of an investigation into the allegations contained in the TikTok videos. The claims therefore remain unverified.

The episode nonetheless underscores the growing influence of social media in raising consumer concerns and the need for regulators to respond with evidence-based scrutiny.

Also read: NAFDAC-Labour Standoff Escalates in Lagos Over Sachet Alcohol Ban

For parents and manufacturers alike, the central issue is clear: confidence in infant care products should rest not solely on viral posts or individual assurances, but on robust quality control, effective regulatory oversight and transparent investigations whenever credible safety concerns emerge.

70 / 100 SEO Score

health

FCCPC Moves Against Producers Over Poorly Fortified Oil, Salt

Published

on

FCCPC orders producers to comply with food fortification standards after a survey found inadequately fortified vegetable oil and salt in Nigerian markets

(more…)

adron lemon friday

68 / 100 SEO Score
Continue Reading

health

UK Tests Five-Day Breast Cancer Radiotherapy in Major Trial

Published

on

The UK is testing five-day breast cancer radiotherapy in a major trial that could reduce hospital visits and treatment costs for patients

The United Kingdom has launched a major clinical trial involving more than 1,000 participants to determine whether breast cancer radiotherapy can be shortened from three weeks to five days without compromising its effectiveness in preventing the disease from returning.

Also read: Grey CEO Urges Africa to Ditch Dollar for Trade

adron lemon friday

The government-funded FAST-Forward Boost trial, being conducted at 39 hospitals across the UK, will investigate whether a shorter course of radiotherapy combined with an additional targeted dose, known as a boost, can provide effective treatment for patients following breast cancer surgery.

The UK Department of Health and Social Care announced the development on Friday, October 30, describing the study as part of efforts to improve cancer treatment and make care more convenient for patients.

Led by the Institute of Cancer Research in London and funded by the National Institute for Health and Care Research, the study aims to recruit 4,830 participants by 2028.

Those enrolled will be followed up for five years, with results expected in 2033.

If the approach proves successful, it could reduce the number of hospital visits required by patients, potentially saving them 10 journeys compared with the existing three-week treatment schedule.

The department said the shorter schedule could also reduce transport expenses and the time patients spend away from work and family.

It could additionally ease pressure on the National Health Service by freeing up radiotherapy capacity for other patients.

Health and Social Care Secretary Yvette Cooper said the trial reflected the country’s efforts to use medical research to improve cancer care.

“This trial shows how the UK is using our world beating research capabilities to pursue huge improvements and transformations in cancer treatment for patients,” she said.

Why the radiotherapy trial matters

Radiotherapy uses carefully targeted radiation to destroy cancer cells or prevent them from growing.

For many people with breast cancer, it is recommended after surgery to reduce the risk of the disease returning in the treated area.

A treatment boost involves delivering an additional dose of radiation to the area considered to have a higher risk of recurrence, usually the site where the tumour was removed.

The FAST-Forward Boost trial is examining how this additional treatment can be incorporated into a shorter schedule.

Reducing treatment from three weeks to five days could make a considerable difference to patients who must travel regularly to hospitals.

The impact may be particularly significant for people living far from specialist cancer centres, those with limited transport options and patients balancing treatment with employment or family responsibilities.

However, the trial is designed to establish whether the shorter approach is effective and safe for the patients being studied. Its results will be important in determining whether the treatment schedule can become a wider option in clinical practice.

UK expands breast cancer screening efforts

The announcement comes as the British government intensifies efforts to improve breast cancer screening, encourage early diagnosis and strengthen support for patients.

The Department of Health and Social Care said screening uptake among women receiving their first invitation had risen to 63.6 per cent, its highest level in a decade.

Despite the improvement, around four in 10 women invited for their first screening appointment still do not attend.

The government is also working with the National Institute for Health and Care Research and NHS England on studies examining how artificial intelligence could support the analysis of mammograms.

The technology is being explored as a way to assist the assessment of breast screening images, although its role and effectiveness must be established through appropriate research and clinical evaluation.

In addition, the government has partnered with breast cancer charity Breast Cancer Now for three years to help women recognise symptoms, find reliable information and access support after treatment.

Together, the initiatives reflect a broader approach to breast cancer care, combining screening, research into treatment improvements and support for people living with the disease.

Also read: Grey CEO Urges Africa to Ditch Dollar for Trade

For now, the five-day radiotherapy approach remains under investigation. With final results not expected until 2033, the FAST-Forward Boost trial will need to establish whether reducing treatment time can deliver comparable cancer control while maintaining patient safety.

65 / 100 SEO Score
Continue Reading

health

DR Congo Faces Deadly Ebola Surge, WHO Warns

Published

on

The DR Congo Ebola outbreak is recording 50 to 80 new confirmed cases daily, with about 10,000 cases and nearly 5,000 deaths reported

(more…)

adron lemon friday

57 / 100 SEO Score
Continue Reading

Trending News